Nodexus Inc.

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Nodexus Inc. - overview

Established

2014

Location

Berkeley, CA, US

Primary Industry

Biotechnology

About

Nodexus Inc. specializes in advanced cell sorting technology, focusing on innovative systems that facilitate gentle cell sorting and dispensing for biological research applications. Nodexus Inc. was founded in 2014 in Berkeley, US to develop advanced cell sorting and dispensing systems.


The company has not pivoted in its core business strategy and operates without subsidiaries. It was co-founded by Karthik Balakrishnan and Vincent Tuminelli, with Karthik Balakrishnan serving as the CEO. In December 2021, Nodexus raised USD 30 mn in Series A funding, led by RA Capital with participation from Section 32, bringing the total amount raised to USD 30 mn. Nodexus specializes in advanced cell sorting and dispensing systems, primarily focusing on the NX One and NX One MAX platforms.


These systems utilize microfluidic technology designed for gentle cell sorting and single-cell dispensing, catering to disease research and drug discovery. Target customers include biotech and pharmaceutical companies, and academic research institutions, with a global market presence in North America, Europe, and Asia. Nodexus generates revenue through the sale of its NX One and NX One MAX cell sorting systems, along with associated microfluidic cartridges. The transaction structure is primarily B2B, engaging directly with research institutions and laboratories.


The core systems are priced under USD 100,000, supplemented by consumable cartridges that require periodic replacement, ensuring ongoing revenue streams. Following its recent funding of USD 30 mn in December 2021, Nodexus plans to significantly expand its team to further its mission of democratizing biological tools. The company is focused on launching new products and expanding into new markets, although specific new product launches and targeted regions have not been detailed. The funds raised will be utilized to support these initiatives, enhancing their operational capacity and market reach.


Current Investors

RA Capital Management, Section 32

Primary Industry

Biotechnology

Sub Industries

Biotechnology

Website

www.nodexus.com/

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.